U.S. FDA OKs Quoin’s Second Netherton Syndrome Clinical Study
The U.S. Food and Drug Administration (FDA) has cleared a second Netherton Syndrome (NS) pivotal clinical study from Quoin Pharmaceuticals Ltd. Quoin’s lead product, QRX003, is a topical lotion formulated with a broad-spectrum serine protease inhibitor that has been shown to significantly downregulate the hyperactivity of the kallikreins in the skin responsible for the excessive […]